Affymetrix received US Patent No. 6,524,800, “Exploiting genomics in the search for new drugs.” The patent covers a system for studying the relationships among drugs and genes by monitoring changes in messenger RNA levels in treated cells with high-density oligonucleotide probe arrays for comparing the specificity of drugs and for detecting alternate targets for drug screening and development by monitoring the expression of genes affected by a drug or mutation.
Affymetrix received US Patent No. 6,525,185, “Polymorphisms associated with hypertension.” The patent covers a collection of polymorphic sites in genes that may play a role in hypertension. The method described provides nucleic acids, including such polymorphic sites. The nucleic acids can be used as probes or primers, or for expressing variant proteins. The invention also provides methods of analyzing the polymorphic forms occupying the polymorphic sites.
Incyte Genomics, now Incyte, has received US Patent No. 6,524,579, “Human RNA binding process.” The patent covers a method for providing human RNA binding proteins (RNABP) and polynucleotides that identify and encode RNABP. The system also provides expression vectors, host cells, antibodies, agonists, and antagonists and methods for diagnosing, treating or preventing disorders associated with expression of RNABP. Oligonucleotides derived from the polynucleotide sequences created may be used in a microarray.
Incyte Pharmaceuticals, now Incyte, has also received US Patent No. 6,519,583, 'Graphical viewer for biomolecular sequence data.' The patent covers a system for graphically displaying computer-based information on biomolecular sequences.